Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: IDYA stock price vs AMAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMAT's multiple
Needs AMAT P/S.
Implied fair value · at IDYA's multiple
Needs IDYA P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · AMAT FY 2025 (ended Oct 26, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
IDEAYA Biosciences, Inc. · implied price per share
Bear
$0.30
Base
$0.35
Bull
$0.41
APPLIED MATERIALS INC /DE · implied price per share
Bear
$93.60
Base
$110.12
Bull
$126.64
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
0.32x
Net debt / EBITDA
Leverage against operating earnings
5.09x
-0.20x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$8.57B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
LAM RESEARCH CORP
IDYA vs LRCX
ASML HOLDING NV
IDYA vs ASML
TERADYNE, INC
IDYA vs TER
MKS INSTRUMENTS INC
IDYA vs MKSI
KLA CORP
IDYA vs KLAC
SKYWORKS SOLUTIONS, INC.
IDYA vs SWKS
$70.35M
$6.56B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
